FDA Approved: PROCYSBI — Supplemental Application (Horizon Therapeutics USA, Inc.)

View source ↗

Summary

FDA approves a supplemental application for PROCYSBI (cysteamine bitartrate) submitted by Horizon Therapeutics USA, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephropathic Cystinosis

Drugs mentioned

• Procysbi (mercaptamine bitartrate)

Snippet

SUPPL AP for PROCYSBI (CYSTEAMINE BITARTRATE)